Outcome of in Vitro Fertilization in Patients with Proven Poor Ovarian Responsiveness After Early Vs. Mid-follicular LH Exposure: a Prospective, Randomized, Controlled Study

Overview

Journal J Assist Reprod Genet

Publisher Springer

Specialties Genetics
Reproductive Medicine

Date 2012 May 31

PMID 22644636

Citations 6

Authors

Alberto Revelli

Alessandra Chiado

Daniela Guidetti

Francesca Bongioanni

Valentina Rovei

Gianluca Gennarelli

Affiliations

Soon will be listed here.

Abstract

Objective: To compare early vs. mid-follicular exposure to LH in patients with poor ovarian responsiveness undergoing in vitro fertilization (IVF).

Design: Prospective, randomized, controlled trial.

Setting: University Hospital, University-affiliated private Clinic.

Patients: Five hundred-thirty women with poor ovarian responsiveness during the first IVF cycle, undergoing their second IVF attempt.

Interventions: In a GnRH-analogue long protocol, ovarian stimulation with recombinant FSH (300 IU/day) plus randomly assigned addition of recombinant LH (150 IU/day) from day 1 (early LH exposure; n = 264) or from day 7 (late LH exposure; n = 266).

Main Outcome Measure(s): Primary outcome was the number of oocytes retrieved. Secondary outcomes were: cancellation rate, total gonadotropin dose, duration of ovarian stimulation, number of embryos available for transfer, pregnancy rate per started cycle, per OPU and per embryo transfer, implantation rate, delivered/ongoing pregnancy rate.

Results: Apart from the totally administered LH dose, that was significantly higher in the group receiving it from day 1, all parameters related to IVF outcome were non significantly different in the two groups.

Conclusions: Adding LH to FSH from day 1 or from day 7 of ovarian stimulation in a GnRH-agonist long protocol exerts comparable effects on IVF outcome in poor responders.

Citing Articles

Clinical pregnancy outcomes prediction in vitro fertilization women based on random forest prediction model: A nested case-control study.

Yang H, Liu F, Ma Y, Di M Medicine (Baltimore). 2023; 101(49):e32232.

PMID: 36626443 PMC: 9750545. DOI: 10.1097/MD.0000000000032232.

Effect of Exogenous Luteinizing Hormone (LH) Supplementation on Clinical Pregnancy of Patients Receiving Long-Acting Gonadotropin-Releasing Hormone Agonist (GnRHa) Cycles: A Retrospective Cohort Study.

Huang C, Shi Q, Yan Y, Shen X, Shan H, Zhu Y Int J Womens Health. 2022; 14:1691-1700.

PMID: 36536609 PMC: 9759025. DOI: 10.2147/IJWH.S388726.

A cohort study of both human menopausal gonadotropin (HMG) and recombinant luteinizing hormone addition at early follicular stage in in vitro fertilization outcome: A STROBE-compliant study.

Xia X, Shi Y, Geng L, Liu D, Hou Z, Lin H Medicine (Baltimore). 2019; 98(19):e15512.

PMID: 31083194 PMC: 6531138. DOI: 10.1097/MD.0000000000015512.

Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: An RCT.

Tehraninejad E, Farshbaf Taghinejad M, Hossein Rashidi B, Haghollahi F Int J Reprod Biomed. 2017; 15(7):435-440.

PMID: 29177245 PMC: 5601935.

Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.

Revelli A, Pettinau G, Basso G, Carosso A, Ferrero A, Dallan C Reprod Biol Endocrinol. 2015; 13:77.

PMID: 26209525 PMC: 4514947. DOI: 10.1186/s12958-015-0080-6.

References

Barrenetxea G, Agirregoikoa J, Jimenez M, de Larruzea A, Ganzabal T, Carbonero K . Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril. 2007; 89(3):546-53. DOI: 10.1016/j.fertnstert.2007.03.088. View

Filicori M, Cognigni G, Gamberini E, Parmegiani L, Troilo E, Roset B . Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005; 84(2):394-401. DOI: 10.1016/j.fertnstert.2005.02.036. View

Platteau P, Nyboe Andersen A, Loft A, Smitz J, Danglas P, Devroey P . Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles. Reprod Biomed Online. 2008; 17(2):190-8. DOI: 10.1016/s1472-6483(10)60194-0. View

Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell J, Balasch J . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril. 2006; 85(4):925-31. DOI: 10.1016/j.fertnstert.2005.09.049. View

Filicori M, Cognigni G, Samara A, Melappioni S, Perri T, Cantelli B . The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update. 2002; 8(6):543-57. DOI: 10.1093/humupd/8.6.543. View

Kolibianakis E, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem A . Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril. 2003; 79(4):873-80. DOI: 10.1016/s0015-0282(02)04920-8. View

Al-Inany H, Abou-Setta A, Aboulghar M, Mansour R, Serour G . Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008; 16(1):81-8. DOI: 10.1016/s1472-6483(10)60559-7. View

Durnerin C, Erb K, Fleming R, Hillier H, Hillier S, Howles C . Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod. 2007; 23(2):421-6. DOI: 10.1093/humrep/dem388. View

Lahoud R, Al-Jefout M, Tyler J, Ryan J, Driscoll G . A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates. Hum Reprod. 2006; 21(10):2645-9. DOI: 10.1093/humrep/del219. View

10.

Weghofer A, Munne S, Brannath W, Chen S, Tomkin G, Cekleniak N . The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Hum Reprod. 2008; 23(3):499-503. DOI: 10.1093/humrep/dem412. View

11.

Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A . Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril. 2010; 94(6):2467-9. DOI: 10.1016/j.fertnstert.2010.04.035. View

12.

Berkkanoglu M, Isikoglu M, Aydin D, Ozgur K . Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor.... Fertil Steril. 2007; 88(3):665-9. DOI: 10.1016/j.fertnstert.2006.11.150. View

13.

Biasoni V, Patriarca A, Dalmasso P, Bertagna A, Manieri C, Benedetto C . Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF. Reprod Biol Endocrinol. 2011; 9:112. PMC: 3162895. DOI: 10.1186/1477-7827-9-112. View

14.

Yanaihara A, Yorimitsu T, Motoyama H, Ohara M, Kawamura T . The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome. J Assist Reprod Genet. 2008; 25(4):115-8. PMC: 2582073. DOI: 10.1007/s10815-008-9205-6. View

15.

Kim Y, Ku S, Jee B, Suh C, Kim S, Choi Y . Tri-pronucleated zygotes may occur less frequently in luteinizing hormone activity-added cycles. Gynecol Endocrinol. 2010; 27(7):458-63. DOI: 10.3109/09513590.2010.501878. View

16.

Kovacs P, Kovats T, Kaali S . Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertil Steril. 2009; 93(2):475-9. DOI: 10.1016/j.fertnstert.2008.12.010. View

17.

Maguire M, Csokmay J, Segars J, Payson M, Armstrong A . Enough is enough! Patients who do not conceive on 600 IU/d of gonadotropins show no improvement from an additional 150 IU of LH activity. Fertil Steril. 2010; 95(1):372-3. PMC: 3005079. DOI: 10.1016/j.fertnstert.2010.08.020. View

18.

Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A . Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2010; 95(3):1031-6. DOI: 10.1016/j.fertnstert.2010.10.021. View

19.

Gutman G, Barak V, Maslovitz S, Amit A, Lessing J, Geva E . Recombinant luteinizing hormone induces increased production of ovarian follicular adiponectin in vivo: implications for enhanced insulin sensitivity. Fertil Steril. 2008; 91(5):1837-41. DOI: 10.1016/j.fertnstert.2008.02.006. View

20.

Hugues J, Soussis J, Calderon I, Balasch J, Anderson R, Romeu A . Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod. 2004; 20(3):629-35. DOI: 10.1093/humrep/deh682. View